Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg®, 2C4) in breast cancer cells
Date
2008
Authors
Canbay, E.
Gur-Dedeoglu, B.
Bozkurt, B.
Karabeyoglu, M.
Unal, B.
Yildirim, O.
Cengiz, O.
Yulug, I. G.
Editor(s)
Advisor
Supervisor
Co-Advisor
Co-Supervisor
Instructor
Source Title
Gene Therapy and Molecular Biology
Print ISSN
1529-9120
Electronic ISSN
Publisher
Gene Therapy Press
Volume
12
Issue
2
Pages
293 - 300
Language
English
Type
Journal Title
Journal ISSN
Volume Title
Attention Stats
Usage Stats
4
views
views
19
downloads
downloads
Series
Abstract
Pertuzumab (Omnitarg®, 2C4) is a recombinant humanized monoclonal antibody targeted to extracellular region of HER-2. Previous results proved the inhibitory effect of Pertuzumab on the survival of breast cancer cells via MAPK and Akt pathway. Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. Here, we aimed to investigate the effects of Pertuzumab on ligand activated total FAK expression and phosphorylation in the HER-2 overexpressing BT-474 breast cancer cell line. Heregulin was used for ligand activation. We have found that FAK expression and phosphorylation were inhibited in with Pertuzumab in breast cancer cells.